CytoMed Therapeutics (NASDAQ:GDTC) Announces Earnings Results

CytoMed Therapeutics (NASDAQ:GDTC) announced its quarterly earnings results on Wednesday. The company reported ($0.06) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.06 million for the quarter.

CytoMed Therapeutics Price Performance

GDTC opened at $0.90 on Friday. The firm has a 50 day moving average price of $0.90 and a 200-day moving average price of $0.98. CytoMed Therapeutics has a twelve month low of $0.68 and a twelve month high of $3.68.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GDTC shares. Fundamental Research set a $4.16 price target on shares of CytoMed Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.16.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited is a Singapore-based clinical-stage biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research centers on using immune cells to recognize and attack tumor cells, with an emphasis on developing treatments that may be suitable for broader use than certain patient-specific therapies.

CytoMed is developing a pipeline of investigational therapies based on technologies involving gamma delta T cells, natural killer T cells and other immune-cell platforms.